Rudolf Uhliar, Martin Gajdoš, Jaroslava Štrbová
The article provides a review of available information about the place of aldosterone antagonists in the treatment of chronic heart failure (HF). It shows importance of aldosterone in heart failure pathophysiology; it describes pharmacological and pharmacokinetic differences among aldosterone antagonists and brings a review of clinical outcomes of chronic HF therapy by aldosterone antagonists, as well as points out the adverse events of this treatment. Aldosterone antagonists represent a part of standard HF treatment of patients after myocardial infarction or severe forms of chronic HF and new clinical studies should prove the place of these drugs also in patients with mild clinical signs and symptoms of HF.